Key result
Patients with combined COPD and CHD had significantly elevated levels of Lipoprotein (a) and PAPP-A compared to healthy controls, suggesting their potential as biomarkers for early CHD diagnosis.
Why the study?
The study was conducted to identify the significance of biomarkers characterizing lipid disorders and atherosclerotic plaque destruction for the early diagnosis of CHD in patients with COPD.
Do elevated levels of Lipoprotein (a) and Pregnancy Associated Plasma Protein A identify the presence of coronary heart disease in patients with chronic obstructive pulmonary disease?
Cross-Sectional (n=183)
Do elevated levels of Lipoprotein (a) and Pregnancy Associated Plasma Protein A identify the presence of coronary heart disease in patients with chronic obstructive pulmonary disease?
Absolute Event Rate: 6.34% vs 3.12%
p-value: p=<0.05
Elevated levels of LP(a) and PAPP-A may serve as useful biomarkers for the early diagnosis of coronary heart disease in men with chronic obstructive pulmonary disease.
OBJECTIVE: The aim: To identify the significance of biomarkers characterizing the role of lipid disorders and the processes of destruction atherosclerotic plaque for the early diagnosis of CHD in patients with COPD. PATIENTS AND METHODS: Materials and methods: There were examined 153 patients, men aged 40-70 years, including 53 patients with COPD, 56 with a combination of COPD and CHD and 44 patients with stable CHD. The level of LP (a) and PAPP-A in the serum was determined by ELISA. RESULTS: Results: There was increased level of LP (a) and PAPP-A in patients with CHD and with a combination of COPD and CHD. This increased level of LP (a) and PAPP-A was associated with the level of C-reactive protein. The mid level of LP (a) and PAPP-A in patients with COPD did not significantly differ from the reference values. CONCLUSION: Conclusions: The increase level of lipoprotein (a) more than 18 mg/dl in patients with COPD may be regarded as a predictor of the development of CHD. The level PAPP-A more than 5 mIU/L in plasma of patients with COPD makes it possible to isolate the groups for CHD risk. The definition of LP (a) and PAPP-A in patients with COPD may contribute to the early diagnostics of coronary heart disease in the absence of its pronounced clinical manifestations.
No takes yet. Share an insight, caveat, or question.
Сєркова et al. (2020) conducted a cross-sectional in Coronary heart disease and chronic obstructive pulmonary disease (n=183). Combined COPD and CHD vs. Healthy controls was evaluated on Serum PAPP-A level (mIU/L) (p=<0.05). Patients with combined COPD and CHD had significantly elevated levels of Lipoprotein (a) and PAPP-A compared to healthy controls, suggesting their potential as biomarkers for early CHD diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: